SavedAdd your journal

Journals / Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2016 / Cilt: 27 - Sayı: 2

The Efficacy and Safety of Ertapenem Therapy in Children with Urinary Tract Infections due to ESBL-Producing Microorganisms

Çocuklarda Ertapenem Tedavisinin GSBL Üreten Mikroorganizmaların Sebep Olduğu İdrar Yolu Enfeksiyonlarında Etkinlik ve Güvenilirliği

Yasemin AKIN
Özge KARATAŞ
Nuran KÜÇÜK
Ayşe KARAASLAN
Esra ÇELIK KUZAYTEPE
Melis ŞIRINOĞLU
Serap GENÇ YÜZÜAK
Demet HACISEYITOĞLU
Pages
134–137
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Ertapenem can be used safely to treat UTI in children caused by ESBL-producing microorganisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study, we evaluated the clinical efficacy and safety of ertapenem treatment for urinary tract infections (UTIs) in children.
📊
Key Findings & Data:Methods: In this retrospective study, we analyzed the records of 22 patients, aged 5 months to 153 months, who received ertapenem therapy for UTI caused by extended spectrum beta-lactamase (ESBL)-producing microorganisms between August 2015 and June 2016.
💡
Conclusion & Impact:Conclusion: Ertapenem can be used safely to treat UTI in children caused by ESBL-producing microorganisms.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: In this study, we evaluated the clinical efficacy and safety of ertapenem treatment for urinary tract infections (UTIs) in children. Methods: In this retrospective study, we analyzed the records of 22 patients, aged 5 months to 153 months, who received ertapenem therapy for UTI caused by extended spectrum beta-lactamase (ESBL)-producing microorganisms between August 2015 and June 2016. Results: Sixteen (72.7%) female and 6 (27.2%) male children with a mean age of 53.0±43.6 months (range: 5 to 153 months) were enrolled in the study. Escherichia coli (n=21), and Klebsiella pneumoniae (n=1) were identified in the urine cultures of these 22 patients. Treatment duration was 10 days for all patients. No adverse drug-related effects were seen. Conclusion: Ertapenem can be used safely to treat UTI in children caused by ESBL-producing microorganisms.

Özet

Amaç: Bu çalışmada idrar yolu enfeksiyonlarında (İYE) ertapenem tedavisinin klinik etkinlik ve güvenilirliğini araştırdık.Gereç ve Yöntem: Geriye dönük olarak yapılan çalışmamıza Ağustos 2015 ve Haziran 2016 tarihleri arasında İYE nedeniyle ertapenem tedavisi alan yaşları 5 ila 153 ay arasında değişen 22 olgu dahil edildi.Bulgular: Olguların 16'sı kız (%72.7), altısı erkek (%27.2), ortalama yaş 53.0±43.6 ay, (dağılım, 5 -153 ay) olarak saptandı. Yirmi iki hastanın idrar kültüründe Escherichia coli (n=21) ve Klebsiella pneumoniae (n=1) saptandı. Olguların hepsinde tedavi süresi 10 güne tamamlandı. Tedavi sırasında olgularda herhangi bir yan etki görülmedi.Sonuç: Çocuklarda GSBL üreten mikroorganizmaların neden olduğu İYE'larında ertapenem güvenli olarak kullanılabilmektedir

🔖

Cite This Article

AKIN, Y., KARATAŞ, Ö., KÜÇÜK, N., KARAASLAN, A., KUZAYTEPE, E. Ç., ŞIRINOĞLU, M., YÜZÜAK, S. G., HACISEYITOĞLU, D. (2022). The Efficacy and Safety of Ertapenem Therapy in Children with Urinary Tract Infections due to ESBL-Producing Microorganisms. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 27 - Sayı: 2, 134–137. https://ajindex.com/articles/571288

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Söylemezoğlu O. Urinary tract infections. In: Hasanoğlu E, Düşünsel R, Bideci A, editors. Basic pediatrics. Ankara: Güneş Tıp Kitapevleri; 2010. p. 929–35
  2. National Institute for Health and Clinical Excellence: Guidance. Urinary Tract Infection in Children: Diagnosis, Treatment and Long-term Management. London: RCOG Press; 2007
  3. Çelebi S, Yüce N, Çakır D, Hacımustafaoğlu M, Özkaya G. Risk Factors for and Clinical Outcomes of Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Children: Results of a 5 Year Study. J Pediatr Inf 2009;3:5–10
  4. Demir N, Gençer S, Özer S, Doğan M. Genişlemiş spektrumlu β-laktamaz üreten gram negatif bakteri infeksiyonları için çeşitli risk fakörlerinin araştırılması. Flora 2008:13;179– 88
  5. Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, Kiyak A, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int 2012;54:858–62
  6. Conkar S, Demirkaya S. Distribution of community-acquired gram negative microorganisms detected in urine samples of pediatric patients and antibiotic resistance patterns at 2013. Dicle Medical Journal 2015;42:181–5
  7. UpToDate Database. http://www.uptodate.com/contents/ combination-beta-lactamase-inhibitorscarbapenemsandmonobactams?source=machineLearning&search=ertap enem&selectedTitle=5~36§ionRank=1&anchor=H3- #H3
  8. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65:2151– 78
  9. Elder JS. Urinary tract infections. In: Kliegman RM, Behrman R, Jenson H, Stanton B, editors. Nelson textbook of pediatrics. Philadelphia, Pa, USA: Saunders Elsevier; 2007. p. 2223–8
  10. CLSI. Performance standards for antimicrobial susceptibility testing; 25th Informational Supplement. CLSI Document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
  11. Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013;34:940–6
  12. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657– 86
  13. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682–90
  14. Dalgic N, Sancar